SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SRX Global (NYSE American: SRXH) updated investors on its pending acquisition of CERo Therapeutics after Pfizer announced a separate licensing deal with Starna Therapeutics. Under a definitive purchase agreement, CERo would become a wholly owned SRX subsidiary. Neither SRX nor CERo is involved in the Pfizer–Starna deal, which carries a $330 million upfront payment. SRX said it does not view that deal as a valuation benchmark for CERo.
CERo reported seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial of CER-1236, an investigational engineered T-cell therapy for blood cancers. The seventh patient was the fourth in the second dose group. The three previously treated patients in that group had no dose-limiting toxicities during the assessment window. CERo also activated UC Davis as a trial site. The findings are preliminary and based on few patients; they do not establish safety or efficacy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Definitive purchase agreement would make CERo Therapeutics a wholly owned SRX subsidiary
- Minor pointPhase 1/1b CERTAIN-T trial reached seven patients dosed, including four in the second dose group
- Minor pointSecond dose group had no dose-limiting toxicities in its three previously treated patients during the assessment window
- Minor pointJune safety update reported no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities or severe treatment-related adverse events during the assessment window
- Minor pointInfused CER-1236 cells expanded after administration, as reported by CERo
2 minor points
- Minor pointTrial eligibility broadened to include additional blood disorders beyond acute myeloid leukemia
- Minor pointUC Davis was activated as a trial site and also serves as the primary manufacturing site for CER-1236
Negative
- Moderate pointCERo Therapeutics acquisition remains pending
- Minor pointCER-1236 findings are preliminary and based on a limited number of patients; they do not establish safety or efficacy
Key Figures
- Upfront payment
- $330 million
- Pfizer–Starna licensing agreement
- Development and commercial milestones
- Up to $2.3 billion
- Eligible payments under the Pfizer–Starna licensing agreement
- Programs covered
- 3 pre-IND in vivo CAR-T programs
- Pfizer–Starna licensing agreement
- Patients dosed
- 7 patients
- Ongoing Phase 1/1b CERTAIN-T trial
- Second-cohort dose-limiting toxicities
- No dose-limiting toxicities in 3 previously treated patients
- During the DLT assessment period
Historical Context
-
UC Davis site activation and prior six-patient findings included no DLTs in the second cohort.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
car-t medical
dose-limiting toxicities medical
cytokine release syndrome medical
pharmacokinetics medical
measurable residual disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pfizer’s
SRX’s pending acquisition of CERo Therapeutics provides exposure to CER-1236, a clinical-stage engineered T-cell therapy with seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial
NORTH PALM BEACH, Fla., Nov. 20, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today commented on recent industry activity in engineered T-cell therapies following the November 18, 2026 announcement by Pfizer Inc. (“Pfizer”) of an exclusive licensing agreement with Starna Therapeutics (“Starna”), and provided an update on its pending acquisition of CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo Holdings” and, together with CERo Therapeutics, “CERo”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms.
According to Pfizer’s announcement, the agreement covers three pre-IND in vivo chimeric antigen receptor T-cell (“CAR-T”) programs focused on treating autoimmune diseases. Starna will receive an upfront payment of
CERo’s approach differs in technology, therapeutic focus and stage of development. Its lead investigational product candidate, CER-1236, is being evaluated in patients with hematologic malignancies in the ongoing Phase 1/1b CERTAIN-T trial. CER-1236 is based on CERo’s proprietary Chimeric Engulfment Receptor T cell (“CER-T”) platform, which is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer.
“Pfizer’s agreement with Starna is a clear signal that large pharmaceutical companies continue to commit significant capital to differentiated engineered T-cell platforms, even before those programs reach the clinic,” said Kent Cunningham, Chief Executive Officer of SRX Global. “CERo’s technology and indications are different, and we do not view this transaction as a valuation benchmark for CERo. What it does reinforce is our conviction in the long-term strategic importance of this field. CER-1236 is already being evaluated in patients, and our focus remains on supporting the CERo team as it advances the CERTAIN-T trial and on working toward closing the proposed acquisition.”
On November 3, 2026, CERo announced that it had dosed the seventh patient in CERTAIN-T, the fourth patient in the trial’s second cohort. CERo reported no dose-limiting toxicities (“DLTs”) in the three previously treated second-cohort patients during the DLT assessment period, and has reported expansion of infused CER-1236 cells following administration. In its June 2026 update, CERo reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. CERo has also expanded its clinical trial sites, including the activation of the University of California, Davis, which also serves as the primary manufacturing site for CER-1236. These clinical results are preliminary, are based on a limited number of patients, and are not sufficient to establish the safety or efficacy of CER-1236.
On October 7, 2026, SRX announced that it had entered into a definitive purchase agreement under which CERo Therapeutics will become a wholly owned subsidiary of SRX Global.
About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML, and the protocol has since been amended to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).
About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).
The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed acquisition of CERo Therapeutics by SRX Global, including its expected timing and completion and the satisfaction of closing conditions; industry interest in and investment in engineered T-cell therapies; the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global’s and CERo’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among others, the possibility that the proposed transaction is not completed on the anticipated timeline or at all; the failure to satisfy closing conditions; and the risks inherent in the clinical development of CER-1236, an investigational product candidate. Information in this communication regarding the Pfizer–Starna agreement is based solely on Pfizer’s public announcement, has not been independently verified by SRX, and should not be interpreted as indicating a valuation for CERo or SRX Global or the likelihood of any similar transaction. Information in this communication regarding CERo, CER-1236 and the CERTAIN-T trial is based on information provided or publicly disclosed by CERo. Prior to the closing of the proposed transaction, SRX does not control CERo and cannot guarantee CERo’s clinical, regulatory, or business outcomes.
Certain risks that could cause actual results to differ are set forth in SRX Global’s and CERo’s respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.